Baseline characteristics

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2022-03-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      25

   units

   Participants

groups

1. description

   Patients receive trametinib orally PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease or who achieve less than PR after 4 courses may also receive Akt inhibitor GSK2141795 PO daily on days 1-28. Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Trametinib: Given PO Uprosertib: Given PO

   id

   BG000

   title

   Treatment (Trametinib, Akt Inhibitor GSK2141795)

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            0

         title

         <=18 years

      2. measurements

         1. group Id

            BG000

            value

            13

         title

         Between 18 and 65 years

      3. measurements

         1. group Id

            BG000

            value

            12

         title

         >=65 years

      denoms

      1. counts

         1. group Id

            BG000

            value

            25

         units

         Participants

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Age, Categorical

   unit Of Measure

   Participants

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            42

            upper Limit

            81

            value

            64

      denoms

      1. counts

         1. group Id

            BG000

            value

            25

         units

         Participants

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age, Continuous

   unit Of Measure

   years

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            14

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            11

         title

         Male

      denoms

      1. counts

         1. group Id

            BG000

            value

            25

         units

         Participants

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

4. classes

   1. denoms

      1. counts

         1. group Id

            BG000

            value

            0

         units

         Participants

   param Type

   COUNT_OF_PARTICIPANTS

   population Description

   Race and Ethnicity were not collected from any participant.

   title

   Race and Ethnicity Not Collected

   unit Of Measure

   Participants

5. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            25

      denoms

      1. counts

         1. group Id

            BG000

            value

            25

         units

         Participants

      title

      Canada

   param Type

   NUMBER

   title

   Region of Enrollment

   unit Of Measure

   participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice